Trade Names:Sulfamylon- Powder for solution, topical 5%- Cream, topical 85 mg per gram
Mechanism of action is unknown; however, it is different from sulfonamides.
Topical mafenide is delivered to burned tissue over a 4-h period following application. Peak concentrations of the cream and solution formulations in burned skin occur at 2 and 4 h, respectively. Following application of the cream, plasma C max occurs in 2 h with levels ranging from 26 to 197 mcg/mL.
Once absorbed, mafenide is rapidly converted to an inactive metabolite.
The metabolite is eliminated through the kidneys. Parent drug and the metabolite blood levels decrease to pretreatment levels within 24 h after application.
Use as adjunctive treatment of second- and third-degree burns.Solution
Use as an adjunctive topical antimicrobial agent to control bacterial infections when used under moist dressings over meshed autografts or excised burn wounds.
Standard considerations. It is not known if there is cross-sensitivity to other sulfonamides.
Apply 1 to 2 times daily, to a thickness of about 1/ 16 inch.Solution
Cover grafted area with 1 layer of fine mesh. Cut an 8-ply burn dressing to the size of the graft and wet with mafenide acetate 5% solution using an irrigation syringe and/or irrigation tubing until leaking is noticeable. If irrigation tubing is not used, the gauze dressing may be moistened every 6 to 8 h as needed to keep it wet. Safety and efficacy have not been established for treatment longer than 5 days for an individual graft procedure.
Store undiluted packets at 59° to 86°F. Store prepared solution at 59° to 86°F for up to 28 days in an unopened container. Once container is opened, any unused solution must be discarded within 48 h.Cream
Avoid temperatures above 104°F. Protect from light.
None well documented.
None well documented.
Rash (5%); itching (3%); blisters; erythema; facial edema; hives; swelling.
Bone marrow depression (rare); eosinophilia; fatal hemolytic anemia.
Burning sensation; pain.
Decreased pCO 2 ; increased serum chloride; metabolic acidosis.
Acute porphyria (rare).
Monitor the site for bacterial growth during interruption of treatment (eg, acidosis, allergic reaction). Monitor acid-base balance, especially in patients with extensive second-degree or partial-thickness burns, and in those patients with pulmonary or renal dysfunction.
Category C .
Safety and efficacy not established in children younger than 3 mo of age.
Safety and efficacy not established.
If allergic reactions occur, consider discontinuing treatment.
Use with caution in patients with acute renal impairment.
Mafenide cream contains sodium metabisulfite, which may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or severe asthmatic episodes in susceptible people.
May occur. If acidosis becomes difficult to control, discontinuing the soaks for 24 to 48 h may aid in restoring acid-base balance.
May occur concurrently with reduction of bacterial growth in the burn wound. Systemic fungal infection through the burn wound is rare.
Fatal hemolytic anemia with DIC, presumably related to G-6-PD deficiency, has been reported.
Masked hyperventilation with resulting respiratory alkalosis has occurred.
May occur as a result of carbonic anhydrase inhibition, usually compensated by hyperventilation. The carbonic anhydrase inhibition may be exaggerated in patients with renal function impairment.
Data are lacking.
Copyright © 2009 Wolters Kluwer Health.